Night Vision and Scotopic Behavioral Function: Quantifying Rod-Pathway Performance in Preclinical Models

Dim-light vision is not determined only by photon capture and phototransduction. Light must also pass through the outer nuclear layer before reaching the photoreceptor outer segments. In nocturnal mammals, including laboratory mice, and independent of their phylogenetic relationship, rod nuclei acquire an inverted chromatin architecture during development that reduces large-angle light scattering and the resulting image veil (Solovei et al. (Cell 2009)).

TG-LBR mice retain non-inverted rod nuclear architecture while preserving rod structure, allowing the optical contribution of nuclear organization to be tested. Compared with wild-type mice, they show worse scotopic contrast sensitivity and markedly poorer near-threshold motion detection at moonlight-like luminance. This provides a direct example of how a retinal optical property can affect behavioral visual performance.

Full-field ERG can provide complementary information about retinal electrical responses, but it does not directly measure retinal contrast transmission or the behavioral consequence of altered light scattering. Scotopic optomotor testing therefore provides a useful functional endpoint alongside optical, structural, and electrophysiological measurements.

Neurodegenerative processes can affect retinal cell populations selectively, producing functional changes that may emerge under low-light conditions before they are apparent in standard photopic assessments. In models with rod-targeted pathology, photopic visual acuity can remain relatively preserved even as rod synapses, outer segments, or photoreceptor survival are compromised.

This creates an interpretation challenge: a normal or near-normal high-luminance optomotor result does not necessarily exclude early retinal dysfunction. Detecting these early changes requires functional measurements obtained under luminance conditions that place greater demand on rod-mediated retinal processing.

The rod-specific Vps35 knockout mouse illustrates this problem. Loss of the retromer component VPS35 in rods is associated with synaptic pathology and progressive retinal degeneration, alongside microglial activation, retinal alpha-synuclein-associated pathology, and retinal ganglion cell loss. Yet the earliest measurable behavioral deficit occurs under low-luminance conditions, before a measurable reduction in photopic visual acuity.

For studies of neurodegeneration with possible retinal involvement, a photopic measurement alone can therefore underrepresent early functional change. Low-luminance and higher-luminance measurements should be interpreted together and complemented by structural and electrophysiological endpoints, which help characterize the retinal pathology underlying any behavioral deficit.

Also see: Neurodegenerative Disease and Retinal Degeneration and Inherited Retinal Disease.

Therapeutic strategies, including small-molecule neuroprotection, gene therapy, and cell-based approaches, may aim to preserve or restore rod photoreceptors and rod-driven retinal function. Their effects should therefore be evaluated under low-luminance conditions that place greater demand on rod-mediated vision. Using only higher-luminance optomotor testing in a rod-dominant retinal-dystrophy model can miss a meaningful early functional benefit. Assessing scotopic performance alongside higher-luminance outcomes helps determine whether treatment effects are preferentially expressed under rod-dominated conditions or extend across lighting conditions.

Treatments that preserve photoreceptor number or outer nuclear layer thickness do not necessarily preserve visual performance to the same degree. Functional benefit depends on the survival and integration of photoreceptors, synaptic transmission, downstream retinal processing, and sufficient output through the visual pathway to support behavior.

Retinal dystrophy models also differ substantially in onset, progression rate, genetic mechanism, and the relative timing of rod and cone involvement. A treatment effect observed in a rapidly degenerating Pde6b model may therefore not translate directly to a progressive rhodopsin-associated dystrophy.

Functional assessment should therefore follow disease-relevant outcomes over time and be interpreted alongside structural and electrophysiological data. Under low-luminance conditions, scotopic optomotor testing provides a practical endpoint for testing whether an intervention preserves rod-dominated visual performance.

Also see: Retinal Degeneration and Inherited Retinal Disease, Retinal Degeneration, Blindness, and Retinal Dystrophy.

Rod and cone pathways overlap across the mesopic range, and the luminance at which a response is rod- or cone-dominated depends on the species, stimulus conditions, adaptation state, and retinal location. A reduced optomotor threshold under low luminance can be consistent with rod-pathway dysfunction, but it can also reflect changes in downstream retinal circuits, retinal output, or central visuomotor processing.

Conversely, a preserved higher-luminance result does not prove that cone function is intact, just as a low-luminance deficit does not independently establish a primary rod lesion. Interpretation is particularly difficult in progressive retinal degeneration, where rod loss can cause secondary cone dysfunction and where compensation may temporarily preserve behavior.

A useful study design therefore compares performance across controlled luminance conditions, standardizes dark adaptation, and combines behavioral outcomes with dark- and light-adapted ERG, imaging, histology, or molecular evidence. This provides converging evidence on whether observed functional changes are preferentially expressed in rod-dominated conditions.

From a clinical translation perspective, scotopic endpoints align with the primary symptom (night blindness) in diseases such as retinitis pigmentosa and CSNB, and with the functional outcomes used in clinical trials employing dark-adapted perimetry, dark adaptometry, and the ISCEV scotopic ERG standard. For details on the relevant clinical analogues and their genetic bases (GRM6, TRPM1, NYX mutations in CSNB; PDE6 mutations in retinitis pigmentosa), see Retinal Degeneration and Inherited Retinal Disease.

Scotopic visual performance depends strongly on the rod adaptation state at the time of testing. Recent light exposure bleaches rhodopsin, and recovery requires regeneration of visual pigment through the retinoid cycle. If animals are tested at low-luminance at different stages of recovery, differences in acuity or contrast sensitivity may reflect inconsistent pre-test adaptation rather than disease progression or treatment effect.

For many mouse experiments after moderate light exposure, 30–60 minutes of dark adaptation is a practical starting range for scotopic testing. The required duration can vary with the prior illumination level and duration, strain, age, retinal health, and the sensitivity range of the planned stimulus. Studies designed to probe near-threshold vision or maximal rod sensitivity may require a longer, empirically validated adaptation period.

This is particularly relevant in visual-cycle disorders. Mice carrying the dominant Rpe65 D477G mutation, for example, show delayed chromophore regeneration and slower recovery of rod function after photobleaching, despite broadly preserved steady-state dark-adapted ERG responses. In such models, a fixed duration validated in wild-type animals may not be sufficient to provide equivalent adaptation. Shin et al. (Am J Pathol. 2017)

A reproducible workflow should therefore define and document the prior-light conditions and adaptation duration, minimize light exposure during transfer, and use the same procedure for all animals and time points. A completely light-tight dark-adaptation enclosure permits this workflow in normal laboratory lighting and helps ensure that subsequent scotopic measurements begin from a standardized, protocol-appropriate adaptation state.